Mediterranean Diet and Bacterial Translocation and Immune-activation in Patients With HIV
Changes in Bacterial Translocation and Immune Activation in Patients Infected With HIV After Change to a Supplemented Mediterranean Diet: Two Arms Randomized Prospective Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Felipen Garcia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient ≥ 18 years of age;
- To sign voluntary informed consent;
- Male or female patients with a negative pregnancy test before inclusion in the study;
- Proven HIV infection (with HIV-1 positive antibodies);
- Patient should be on stable treatment with cART for at least 1 year
- The mean of all CD4 measurements during the year prior to the initiation of cART should be equal to greater than 350 cells / mm3
- The number of CD4 + at the time of recruitment must be equal to or greater than 500 cells / mm3;
- HIV viral load should be undetectable at least 6 months prior to study inclusion, and less determinations (occasional blips above the undetectable level are allowed).
Exclusion Criteria:
- Acquired Immunodeficiency Syndrome.
- Active opportunistic diseases.
- Patients coinfected with HCV or HBV
- Coagulopathy
- Renal insufficiency (creatinine> 1.5 mg / dL)
- Pregnancy or breastfeeding
- Inability to sign informed consent
- Active opportunistic infections, or any active infection or cancer within 30 days prior to the screening visit;
- Therapy with immunomodulatory agents, including cytokines (eg IL-2) and gammaglobulins or chemotherapy within 90 days prior to the screening visit;
- Use of anticoagulant medication;
- Use of any type of experimental medication during the 90 days prior to study entry;
- Uncontrolled psychiatric disorder;
- Patients with uncontrolled active autoimmune diseases;
- Usual use of antibiotics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: mediterranean diet
Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
|
a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
|
|
No Intervention: Usual diet
Patients do usual diet for three months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in levels of sCD14 at baseline and month 3 between groups
Time Frame: 2 year
|
parameters of bacterial translocation
|
2 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in EndocAB and LBP levels at baseline and month 3 between groups.
Time Frame: 2 year
|
other parameters of bacterial translocation.
|
2 year
|
|
Changes in microbiota (fecal 16s rRNA) at baseline and month 3 between groups
Time Frame: 2 years
|
Microbioma
|
2 years
|
|
Changes in ultrasensitive PCR, TNF-alpha, IL-6 and Dimer-D at baseline and month 3 between groups
Time Frame: 2 years
|
inflammatory markers
|
2 years
|
|
Changes in lipids at baseline and month 3 between groups
Time Frame: 2 years
|
Lipids
|
2 years
|
|
Changes in expression of CD38, HLA DR in CD4 and CD8 T cells at baseline and month 3 between groups
Time Frame: 2 years
|
immune-activation markers
|
2 years
|
|
Changes in total and integrated DNA
Time Frame: 2 years
|
Marker of HIV reservoir
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Felipe García, MD, PhD, Institut d'Investigacions Biomèdiques August Pi i Sunyer
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Clinic Hospital of Barcelona
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.